RCM
CRSP icon

Riverhead Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Riverhead Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$46K – 1551
2018
Q1 		$46K Buy
+1,000
New +$41.3K ﹤0.01% 1475

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Riverhead Capital Management's CRSP Position: Q2 2018 in Review

Riverhead Capital Management sold out of CRISPR Therapeutics (CRSP) in Q2 2018, closing a stake of 1,000 shares — an estimated $46K sold.

Riverhead Capital Management first reported a position in CRSP in Q1 2018 and held it in 1 quarter. The position peaked at $46K in Q1 2018. 174 funds tracked by Wall St. Rank hold CRSP as of Q2 2018.

  • Riverhead Capital Management reported no remaining CRISPR Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Riverhead Capital Management sold 1,000 CRISPR Therapeutics shares in Q2 2018, an estimated $46K.
  • Riverhead Capital Management first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 1 quarter.
  • Riverhead Capital Management's CRISPR Therapeutics position peaked at $46K in Q1 2018.
  • 174 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2018.

Based on Riverhead Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.